Alpha Teknova, Inc. (TKNO) Stock Price & Analysis
Alpha Teknova, Inc. (TKNO) fell 4.09% to USD 4.46 as of June 10, 2026 at 07:38 UTC, according to Nexqual real-time market data.
TKNO last closed at USD 4.65; the session ranged USD 4.44–4.98 on volume of 149,216 shares. Market capitalization is $239.12M, with a 52-week range of USD 1.91–6.68 (NGM). Source: Nexqual, June 10, 2026 at 07:38 UTC.
Key Statistics (as of June 10, 2026 at 07:38 UTC)
| Price | USD 4.46 |
|---|---|
| Change | ▼ 4.09% (down) |
| Previous Close | USD 4.65 |
| Open | USD 4.65 |
| Day Range | USD 4.44 – 4.98 |
| 52-Week Range | USD 1.91 – 6.68 |
| Volume | 149,216 shares |
| Market Cap | $239.12M |
| Exchange | NGM |
Technical Analysis (TKNO)
Nexqual's technical model rates TKNO "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 07:38 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.59 (neutral) |
| vs SMA50 | Above (USD 3.6) |
| MACD | 0.42 (positive) |
Analyst Ratings (TKNO)
Wall Street analysts rate TKNO "None" based on 3 analysts, with a mean price target of USD 9 (range USD 7–12), per Nexqual as of June 10, 2026 at 07:38 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9 |
| High Target | USD 12 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (TKNO)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $10.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.07 vs est -0.1 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
Financials & Fundamentals (TKNO)
| Total Revenue | $41.80M |
|---|---|
| Revenue Growth (YoY) | +13.10% |
| Gross Margin | +34.01% |
| Operating Margin | -38.80% |
| Profit Margin | -41.07% |
| ROE | -23.92% |
| Debt / Equity | 42.86 |
| Current Ratio | 4.59 |
| Total Cash | $17.78M |
| Total Debt | $27.83M |
| Free Cash Flow | $-2.39M |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
Financial Health Score (TKNO)
Nexqual rates Alpha Teknova, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:38 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $18M cash vs $28M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -24%, ROA -9.3% |
Ownership (TKNO)
| Insider Ownership | +9.32% |
|---|---|
| Institutional Ownership | +84.72% |
| Shares Outstanding | 53.61M |
| Float | 10.88M |
| Short % of Float | +10.17% |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
Leadership (TKNO)
Alpha Teknova, Inc. is led by Stephen Gunstream (age 45), President, CEO & Director, per Nexqual as of June 10, 2026 at 07:38 UTC.
| President, CEO & Director | Stephen Gunstream (age 45) |
|---|---|
| Chief Financial Officer | Matthew C. Lowell (age 54) |
| Senior Vice President of Marketing | Jennifer Henry |
Major Backers & Investors (TKNO)
Notable institutional backers of Alpha Teknova, Inc. include Roubaix Capital, LLC, Royce & Associates LP, ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc, according to Nexqual as of June 10, 2026 at 07:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Roubaix Capital, LLC | 3.51% |
| Royce & Associates LP | 1.99% |
| ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc | 1.23% |
| Millennium Management | 0.83% |
| UBS Group AG | 0.61% |
| Conestoga Capital Advisors, LLC | 0.59% |
| ROYCE FUND-Royce Micro-Cap Fund | 0.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.11% |
| Vanguard Group | 1.64% |
| Geode Capital | 0.57% |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
From Alpha Teknova, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
- The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
- It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
- The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TARA | Protara Therapeutics, Inc. | USD 3.97 | ▼ 4.57% |
| RLYB | Rallybio Corporation | USD 15.91 | ▼ 0.25% |
| SERA | Sera Prognostics, Inc. | USD 2.13 | ▼ 6.99% |
| IPSC | Century Therapeutics, Inc. | USD 2.21 | ▲ 3.76% |
| TCRX | TScan Therapeutics, Inc. | USD 0.97 | ▼ 1.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:38 UTC. This page is informational and not investment advice.